# Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

> **NCT02260544** · PHASE1 · COMPLETED · sponsor: **Dr. Reddy's Laboratories Limited** · enrollment: 49 (actual)

## Conditions studied

- Ovarian Epithelial Cancer Recurrent

## Interventions

- **DRUG:** Doxorubicin Hydrochloride Liposome Injection

## Key facts

- **NCT ID:** NCT02260544
- **Lead sponsor:** Dr. Reddy's Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-04
- **Final completion:** 2015-08
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02260544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02260544, "Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02260544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*